Improving Quality of Life for Over 3% of the World’s Population
When you are studying a condition that affects over 3% of the world population, as dermatitis does, you want to ensure your models are as predictive as possible. PharmaLegacy is a global leader in the development of highly predictive animal models. We have over 300 validated animal models, including non-human primate models and many humanized rodent models. Download our atopic dermatitis brochure and we’ll introduce you to some of our newest models. See why over 300 pharma & biopharma companies across the globe trust PharmaLegacy to perform their preclinical studies.
Providing Better Data for Critical Oncology Pipeline Decisions
To advance a compound from discovery to clinical, or to halt its development, is a huge and costly decision. For the benefit of you and your company, and for the well-being of patients in need of treatment, that decision needs to be based on correct information.
Download our Integrated In Vitro Oncology Assays brochure and see why over 300 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical oncology pipeline decisions.
Top Pharmaceutical Companies Trust PharmaLegacy for their Immunology Studies
Non-human primates (NHP) share significant homology with humans allowing cross reactivity with biologic, cell and gene-based therapies. This permits testing of your treatment without the need to generate a costly rodent surrogate. Additionally, your therapies physiological and histological effects are more likely to be faithfully recapitulated compared to rodent systems.
Download our “Non-Human Primate Models for Immunological Research” brochure to learn more about the many validated models PharmaLegacy offers and see real-world sample data.
